Abstract
In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1, affecting up to 10–15% of cases, have been associated to poor prognosis, disease progression and refractoriness to chemotherapy. NOTCH1 mutations are significantly overrepresented in trisomy 12 CLL, a disease subset frequently expressing CD49d, the α4 chain of the very-late-activation-4 integrin, a well-known key regulator of microenviromental interactions, and negative prognosticator in CLL. In the present study, by analysing a wide cohort of 1180 CLL, we observed a very strong association between the presence of NOTCH1 mutations and the expression of CD49d (P<0.0001), occurring also outside the trisomy 12 CLL subset. Using both the MEC-1 CLL-like cells stably transfected with the NOTCH1 intracellular domain and primary CLL cells bearing a mutated or wild-type NOTCH1 gene configuration, we provide evidence that triggering of the NOTCH1 pathway resulted in a positive CD49d expression regulation, which was driven by a NOTCH1-dependent activation of nuclear factot-κB (NF-κB). Consistently, pharmacological inhibition of the NOTCH1 and/or of the NF-κB pathways resulted in impaired NF-κB nuclear translocation with consequent down-modulation of CD49d expression. Altogether, our data link for the first time NOTCH1 mutations to CD49d expression regulation through the involvement of the NF-κB pathway in CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389–1401.
Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101–105.
Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403–1412.
Schroeter EH, Kisslinger JA, Kopan R . Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998; 393: 382–386.
Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A . Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355–358.
Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A . Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci USA 2006; 103: 9262–9267.
Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia 2015; 30: 182–189.
Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 2014; 28: 1060–1070.
Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269–271.
Rosati E, Sabatini R, Rampino G, Tabilio A, Di IM, Fettucciari K et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856–865.
Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526: 519–524.
Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329–331.
Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012; 97: 437–441.
Athanasiadou A, Stamatopoulos K, Tsompanakou A, Gaitatzi M, Kalogiannidis P, Anagnostopoulos A et al. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. Cancer Genet Cytogenet 2006; 168: 109–119.
Tsimberidou AM, Keating MJ . Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216–228.
Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood 2013; 122: 3317–3321.
Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nuckel H et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014; 32: 897–904.
Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111: 865–873.
Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Del Poeta G et al. Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. Semin Hematol 2014; 51: 168–176.
Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640–1645.
Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood 2007; 109: 2989–2998.
Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P et al. Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia. Haematologica 2017; 102: e305–e309, epub ahead of print 18 April 2017 doi:10.1038/leu.2017.90.
Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM et al. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia 2017.
Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 2016; 127: 2122–2130.
Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123: 2139–2147.
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS et al. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood 2014; 123: 4101–4110.
Josien H . Recent advances in the development of gamma-secretase inhibitors. Curr Opin Drug Discov Dev 2002; 5: 513–525.
Rand MD, Grimm LM, Artavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol 2000; 20: 1825–1835.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.
Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268–281.
Xu ZS, Zhang JS, Zhang JY, Wu SQ, Xiong DL, Chen HJ et al. Constitutive activation of NF-kappaB signaling by NOTCH1 mutations in chronic lymphocytic leukemia. Oncol Rep 2015; 33: 1609–1614.
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009; 114: 4441–4450.
Ntziachristos P, Shan Lim JS, Sage J, Aifantis I . From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell 2014; 25: 318–334.
Burger JA . Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 96–103.
Miyake K, Yamashita Y, Kimoto M . A calcium- or manganese-dependent epitope on the integrin beta 1 chain recognized by a unique mAb. Int Immunol 1994; 6: 1221–1226.
Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J 2006; 25: 129–138.
Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003; 278: 1450–1456.
Lopez-Guerra M, Roue G, Perez-Galan P, Alonso R, Villamor N, Montserrat E et al. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res 2009; 15: 2767–2776.
Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70–77.
Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal BM, Marconi D et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009; 69: 4001–4009.
Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010; 70: 7523–7533.
Fabbri G, Holmes AB, Viganotti M, Scuoppo C, Belver L, Herranz D et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2017; 114: E2911–E2919.
Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F et al. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia 2016; 30: 2011–2018.
Acknowledgements
This study was supported in part by the Associazione Italiana Ricerca Cancro (AIRC), IG-17622 and Special-Program-Molecular-Clinical-Oncology 5 × 1000 No.10007; RF-2011-02349712, GR-2011-02346826, GR-2011-02347441, GR-2011-02351370, Ministero della Salute, Rome, Italy; Ricerca clinica/traslazionale/di base/epidemiologica/organizzativa, Regione FVG (‘Linfo-Check’ Project), Trieste, Italy; Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore Group, Italy; Fondazione per la Vita di Pordenone, Italy; and 5 × 1000 Intramural Program, Centro di Riferimento Oncologico, Aviano, Italy. We thank our patients for participating and donating samples to make this research possible.
Author contributions
AZ and VG designed the study, coordinated the experiments and wrote the manuscript. DB and ET performed the experiments, analysed the data and contributed to write the manuscript. FP, TB, CC, CP, DM, VB, TD, FMR, RB and MDB performed the experiments and contributed to characterize samples and to data analysis. ES, FZ, GP, FDR, GDP, DR and GG contributed to molecular characterization of samples and provided well characterized biological samples. All the authors commented and contributed to write the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Benedetti, D., Tissino, E., Pozzo, F. et al. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. Leukemia 32, 654–662 (2018). https://doi.org/10.1038/leu.2017.296
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.296
This article is cited by
-
CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study
Genes & Immunity (2024)
-
High-resolution Melting Analysis for NOTCH1 c.7541-7542delCT Mutation in Chronic Lymphocytic Leukemia: Prognostic Significance in Egyptian Patients
Indian Journal of Hematology and Blood Transfusion (2022)
-
Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape
Nature Communications (2022)
-
Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS
Leukemia (2019)
-
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
Leukemia (2019)